If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of Azenta, Inc. ( AZTA ) have fallen to fresh lows again amidst quite some corporate developments taking place. By now, shares have fallen to the $20 mark, levels first broken to the upside ...

Marotta said UK Biocentre will continue operating under its own brand and identity. He also highlighted the facility’s location in the UK “Golden Triangle” corridor connecting London, Oxford, and Cambridge, and noted proximity to Azenta’s other UK operations.Marotta emphasized that the UK is a major life sciences hub for genomics, precision medicine, and population studies, supported by public investment and collaboration between public and private sectors. He said UK Biocentre has become a “critical and tr ...

Presentation Operator Hello, and welcome. My name is Jenny, and I will be your conference facilitator today for Azenta's Acquisition of Uk Biocentre Acquisition Call. [Operator Instructions] As a reminder, this conference call is being recorded today, Tuesday, March 10, 2026. I will now turn the conference call over to Yvonne Perron, Vice President, FP&A and Investor Relations. Yvonne PerronVice President of Financial Planning & Analysis and Investor Relations Good morning, everyone, and thank you for jo ...

Summary of Azenta's Acquisition of UK Biocentre Conference Call Company and Industry - **Company**: Azenta - **Acquisition Target**: UK Biocentre - **Industry**: Life Sciences, Biorepository Services Core Points and Arguments 1. **Strategic Rationale for Acquisition**: - The acquisition of UK Biocentre expands Azenta's global footprint and scales its biorepository operations, reinforcing its position in the life sciences industry and enhancing long-term growth prospects [3][4] - UK Biocentre is recognized for its operational excellence and automation capabilities, making it a strategic fit for Azenta [3] 2. **UK Biocentre's Capabilities**: - UK Biocentre is one of the largest automated biorepositories globally, with a storage capacity of over 30 million samples [4] - It utilizes Azenta's BioArc automated biobanks and plans to deploy the BioArc Ultra with a capacity of 16 million samples to enhance its operations [4] 3. **Geographical and Operational Synergies**: - The acquisition strengthens Azenta's presence in Europe, particularly within the UK's life sciences ecosystem, which is supported by strong public investment and collaboration between sectors [5][6] - UK Biocentre's operations align with Azenta's standards, allowing for immediate scaling of throughput and efficiency [6][7] 4. **Financial Aspects of the Acquisition**: - Azenta paid GBP 20.5 million for UK Biocentre, which includes up to GBP 1.8 million in contingent consideration [9] - For the fiscal year ending September 30, 2025, UK Biocentre generated GBP 15.3 million in revenue, reflecting a year-over-year decline due to timing in research program phases [9] 5. **Future Growth Expectations**: - Azenta anticipates that 2026 will be dilutive to adjusted EBITDA by approximately 35 basis points, but expects accretion in 2027 and 2028 driven by volume growth and operational leverage [10] - The company aims to diversify its customer base and accelerate growth in the pharma and biotech sectors through targeted investments [10][15] 6. **Operational Efficiency and Cost Structure**: - UK Biocentre operates at 40% capacity, indicating significant room for growth without requiring additional capital investment [26] - The existing infrastructure allows for higher throughput at the same operational cost, driving margin expansion [29] Other Important Content 1. **Integration and Management**: - UK Biocentre will continue to operate under its own brand, maintaining its reputation for quality and operational excellence [4] - The management team at UK Biocentre is expected to play a crucial role in driving growth in the region [16] 2. **Sales and Marketing Strategy**: - Azenta plans to hire additional sales representatives to enhance its commercial efforts in the pharma and biotech sectors [29] - The integration of UK Biocentre is expected to create cross-border business opportunities with Azenta's German biorepository [16] 3. **Technological Advancements**: - The BioArc Ultra is positioned as a competitive advantage, providing high throughput and efficient sample access [18][20] - Azenta's automated workflows and vertical integration on consumables contribute to a cost-leading position in the market [20] This summary encapsulates the key points discussed during the conference call regarding Azenta's acquisition of UK Biocentre, highlighting the strategic, operational, and financial implications of the transaction.

STRATEGIC ACQUISITION OF UK BIOCENTRE March 10, 2026 © 2026 Azenta, Inc. • All rights reserved Safe Harbor Statement 1 Safe Harbor Statement Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current assumptions, expectations, and beliefs and include, without limita ...

Core Insights - Azenta, Inc. has announced the acquisition of UK Biocentre Limited, enhancing its capabilities in sample management and processing services [1] Company Summary - Azenta, Inc. is a leading provider of life science solutions, indicating a strong position in the industry [1] - The acquisition of UK Biocentre Limited will expand Azenta's service offerings in the United Kingdom, particularly in sample storage and high-throughput processing [1] Industry Summary - The acquisition reflects a growing trend in the life sciences sector towards consolidation, as companies seek to enhance their service capabilities and market reach [1]

Summary of Azenta's Conference Call Company Overview - **Company**: Azenta - **Industry**: Life Sciences Tools and Diagnostics - **Current Business Size**: Approximately $600 million with a growth rate of 3% last year [6][24] - **Recurring Revenue**: 55% of total revenue is recurring [6] - **Total Addressable Market (TAM)**: $6 billion, with Azenta capturing about 10% [6] Key Insights and Core Points Business Opportunities - Azenta operates within a critical ecosystem for top pharmaceutical and biotech companies, managing valuable assets and supporting research throughput [3] - The company has over 150 global stores and thousands of instruments, positioning it well for market share growth [3] - Plans for new product development, increased sales force, and pricing strategies are in place to drive above-market growth [4] Financial Performance and Projections - Azenta aims to generate $200 million to $250 million in free cash flow over the next few years [5][24] - The stock price includes $12-$15 in cash, trading at 8-10 times earnings, indicating strong value potential [5][27] - The company plans to double its EBITDA in the next three years [5] Operational Improvements - Significant restructuring has occurred to reduce G&A costs and improve operational efficiency, including a reduction of 300-350 headcount at corporate [15][16] - The organization has shifted to a decentralized structure, focusing resources on business units rather than a centralized corporate model [14][15] - Implementation of performance metrics, including quality and on-time delivery, has been prioritized to enhance customer satisfaction [17][23] Market Position and Strategy - Azenta's sample management solutions are highlighted as a key business segment, with 90% recurring revenue and gross margins exceeding 55% [12][28] - The multiomics business is also seen as a growth area, providing integrated solutions for gene reading and writing [29] - The company is focused on expanding its biorepository footprint, particularly in Europe, and is exploring M&A opportunities [12][13] Challenges and Turnaround Efforts - The previous management's centralization and operational inefficiencies led to challenges, including quality and delivery issues [11][13] - A turnaround strategy is in place, focusing on operational excellence, customer engagement, and continuous improvement through the Azenta Business System (ABS) [20][21] - Early indicators of success include a reduction in customer complaints by 55% and an increase in on-time delivery from 15% to 65% [22][23] Future Outlook - The company is optimistic about its growth trajectory, with a focus on innovation, commercial excellence, and gross margin improvement [21][22] - Engagement scores among employees have improved, indicating a positive shift in company culture and morale [20] Additional Important Points - Azenta's transition from a semiconductor background to life sciences is seen as an underappreciated aspect of its business model [27][28] - The company is actively working to reposition its sales force to better align with customer needs and market demands [33][34] - The implementation of Kaizen methodologies within ABS has led to significant operational improvements, such as reducing product delivery times from 25 days to 9 hours [39][41] This summary encapsulates the key points discussed during the conference call, highlighting Azenta's strategic direction, financial outlook, operational improvements, and market positioning.

RAYMOND JAMES INSTITUTIONAL INVESTOR CONFERENCE John Marotta, President and Chief Executive Officer Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward- looking statements may be identified by words such as "expect," "estimate," "intend," "believe," " ...

Core Insights - Azenta, Inc. has formed a strategic partnership with Frontier Space to conduct scientific experiments in space, leveraging microgravity to advance life sciences research [1][2] - The collaboration includes participation in the EGGS-2 mission, which aims to test the performance of Frontier's SpaceLab Mk 2 research platform under actual space conditions [1][3] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, offering reliable cold-chain sample management and multiomics services to pharmaceutical, biotech, academic, and healthcare institutions globally [6] - The company operates under several brands, including GENEWIZ, FluidX, and others, and has a presence in North America, Europe, and Asia [6][7] Partnership Details - The partnership allows Azenta to showcase its sample management technologies in challenging research environments, enhancing the application of its high-precision consumables [2] - The EGGS-2 mission involved 42 passive experimental samples using FluidX 0.26mL tubes, selected for their precision and reliability in extreme conditions [3] Research Focus - A significant aspect of the mission was to evaluate the active thermal management capabilities of the SpaceLab Mk 2 platform, which are crucial for life sciences research in microgravity [4] - The mission aims to provide insights into how space conditions can accelerate biological processes, facilitating faster scientific learning cycles [4] Future Implications - The collaboration is seen as a foundational step towards routine pharmaceutical research and biomanufacturing in space, with potential for significant advancements in life sciences [5] - Azenta's involvement in the mission reinforces the reliability of its consumables across various applications in life sciences research [5]

Revenue and Profitability - Revenue for the three months ended December 31, 2025, was $148,642 thousand, a 0.8% increase compared to $147,436 thousand for the same period in 2024[139] - Gross profit for the three months ended December 31, 2025, was $63,706 thousand, resulting in a gross margin of 43%, down from 47% in the prior year[140] - The net loss from continuing operations for the three months ended December 31, 2025, was $5,190 thousand, an improvement from a net loss of $7,073 thousand in the same period of 2024[140] - Total revenue for the three months ended December 31, 2025, was $148.642 million, compared to $147.436 million for the same period in 2024, representing a year-over-year increase of 0.8%[148]. - The operating loss for the three months ended December 31, 2025, was $(7.237) million, compared to an operating loss of $(8.701) million for the same period in 2024, showing an improvement of 16.8%[148]. - Adjusted operating income for the three months ended December 31, 2025, was $544,000, compared to $2.428 million for the same period in 2024, reflecting a decrease of 77.6%[148]. Segment Performance - Revenue from the Multiomics segment increased by approximately 1.4% to $67,217 thousand for the three months ended December 31, 2025, driven by growth in Next Generation Sequencing and Gene Synthesis[145] - The operating loss for the Sample Management Solutions segment was $3,731 thousand for the three months ended December 31, 2025, compared to an operating income of $4,019 thousand in the prior year[147] - The total adjusted operating income for the Multiomics segment was a loss of $4,361 thousand for the three months ended December 31, 2025, compared to a loss of $2,311 thousand in the same period of 2024[147]. - The Multiomics segment reported an operating loss of $5.0 million for the three months ended December 31, 2025, compared to an operating loss of $3.2 million for the same period in 2024, an increase in loss of 56.3%[151]. Expenses and Cost Management - Operating expenses decreased by $6.6 million to $70,943 thousand for the three months ended December 31, 2025, primarily due to lower selling, general, and administrative expenses[140] - Research and development expenses increased to $9.189 million for the three months ended December 31, 2025, up from $7.113 million in the prior year, representing a 29.3% increase[157]. - Selling, general and administrative expenses decreased to $60.611 million for the three months ended December 31, 2025, down from $69.976 million in the prior year, a reduction of 13.5%[158]. - The gross margin for the total company decreased to 42.9% for the three months ended December 31, 2025, compared to 46.7% for the same period in 2024, a decline of 3.8 percentage points[153]. Cash Flow and Financial Position - As of December 31, 2025, the company had cash and cash equivalents, restricted cash, and marketable securities totaling $570.9 million, with stockholders' equity at $1.7 billion[165]. - Cash and cash equivalents increased from $279.8 million on September 30, 2025, to $336.6 million on December 31, 2025, representing a growth of 20.3%[166]. - Net cash provided by operating activities for the three months ended December 31, 2025, was $20.8 million, a decrease of $9.0 million compared to the same period in 2024[168]. - The company repatriated $41.1 million from China during fiscal year 2025 and has $163.6 million of cash held outside the U.S. as of December 31, 2025[167]. - The company had no outstanding debt on its balance sheet as of December 31, 2025[169]. Discontinued Operations - Revenue from discontinued operations related to the B Medical Systems business was $13.1 million for the three months ended December 31, 2025, down from $17.6 million in the prior year, a decrease of 25.4%[164]. - Loss from discontinued operations, net of tax, was $10.2 million for the three months ended December 31, 2025, compared to a loss of $3.9 million for the same period in 2024, reflecting a significant increase in loss[164]. Strategic Initiatives - The company aims to simplify its portfolio and focus on revenue growth and profitability in its core segments following the sale of the B Medical Systems business[132]. - The company entered into a definitive Sale and Purchase Agreement for the sale of B Medical Systems business for $63.0 million, with $9.0 million already deposited[131]. Foreign Operations and Currency Impact - Revenue generated outside the United States was 41.0% for the three months ended December 31, 2025, compared to 36.6% for the same period in 2024[146]. - Approximately 38% of total sales during the three months ended December 31, 2025, were in currencies other than the U.S. dollar, primarily from foreign subsidiaries[174]. - Foreign currency losses of $0.9 million were incurred during the three months ended December 31, 2025, compared to gains of $0.5 million in the same period of 2024[175]. - A hypothetical 100 basis point change in interest rates would result in a $1.0 million change in interest income for the three months ended December 31, 2025[173]. Shareholder Actions - The Board of Directors approved a share repurchase program of up to $250 million through December 31, 2028, with no repurchases made as of the report date[170]. - The company had non-cancellable commitments of $40.9 million, including $18.0 million for inventory purchases and $22.9 million for other operating expenses[171].